Conmed (CNMD) Q2 EPS Jumps 17%
Conmed (NYSE:CNMD), a medical technology company specializing in surgical devices, reported its financial results on July 30, 2025. The headline news from the release was that both GAAP revenue and adjusted earnings per share (non-GAAP) topped analyst projections, with GAAP revenue reaching $342.3 million (versus an expected $338.35 million) and non-GAAP EPS at $1.15 (beating the $1.12 estimate). These results reflected a combination of solid underlying demand for core consumable products and progress in supply chain improvements. However, the company also noted hurdles, including a drop in Capital Products sales (GAAP) and new tariff costs that will impact profit margins in the second half of the year. Overall, the quarter demonstrated selective strength but also signaled important risks to monitor in coming periods.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Conmed is a developer and manufacturer of medical technology, focusing on surgical instruments and devices used in operating rooms worldwide. Its core offerings include devices for minimally invasive procedures, with a substantial part of its business stemming from reusable and single-use surgical products.
Source Fool.com
